Ropes & Gray advised long term client Bain Capital as it led Kailera Therapeutics’ $600 million Series B financing. Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing a differentiated, late-stage portfolio of next-generation therapies for the treatment of obesity.
The financing, which was announced on October 14, will be fully funded at closing and will support the advancement of Kailera’s obesity portfolio, including a global Phase 3 clinical program of Kailera’s lead candidate KAI-9531, an injectable dual GLP-1/GIP receptor agonist.
The Ropes & Gray team was led by venture capital and emerging companies partner Rajarshi Banerjee and counsel Michael Connolly, and included intellectual property transactions partner Melissa Rones and counsel Ryan Murphey, asset management partner Bryan Hunkele, antitrust counsel Deidre Johnson and Derek Yee, employment, executive compensation and employee benefits partners Renata Ferrari and Meg Bisk, life sciences partner Greg Levine, strategic transactions partner Michael Littenberg, data, privacy and cybersecurity partner Ed McNicholas, strategic transactions associate Derek Mubiru, and antitrust associate Ryan Haynes.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.